Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis

The study will evaluate the effectiveness and safety of the investigational drug SB683699 in treating patients with relapsing multiple sclerosis (MS), using data from magnetic resonance imaging (MRI) scans as the main measure.

Inclusion criteria:

• Diagnosis of multiple sclerosis (MS).
• Expanded Disability Status Score 0 - 6.5.
• One or more relapse of MS in previous 12 months.
• Currently not taking any medications for MS (apart from those used to treat symptoms).

Exclusion criteria:

• Patients with significantly abnormal laboratory tests or electrocardiogram (ECG) results.
• Subjects who cannot have MRI scans.
• Women who are pregnant, breast feeding or planning to become pregnant during the study.